Search for Abstracts Find by Title, Author or Description Year Abstracts - 2022 - 2021 - 2020 - 2019 - 2018 - 2017 - 2016 - 2015 - 2014 - 2013 - 2012 - 2011 - 2010 - 2009 Tags AB Applied Basic Science Basic Science BT Clinical Clinical-Chemotherapy-SSA-Biologics Clinical-PRRT-Nuclear Clinical-Surgical-Applied_Pathology OT Other P Population Science Poster T Trials In Progress Search Reset Order by Title Alphabetical Title Reverse Alphabetical Most Recent First Oldest First Most popular first Last modified first C1 - Preliminary Safety, PK/PD, and Antitumor Activity of XmAb18087, an SSTR2 x CD3 Bispecific Antibody, in Patients with Advanced Neuroendocrine Tumors Published in 2020 Listed under Clinical-Chemotherapy-SSA-Biologics Download B. El-Rayes, S. Pant, V. Villalobos, A. Hendifar, W. Chow, B. Konda, M. Reilley, A. Benson, G. Fisher, J. Starr, J. Strosberg, D. Ahn, K. Perez, N. Raj, J. Eads, T. Hobday, S. Chollate, Y. Ding, C. Fleener, J. Shorr ABSTRACT ID: 111 C10 - Treatment Outcomes of Well- Differentiated High-Grade Neuroendocrine Tumors Published in 2020 Listed under Clinical-Chemotherapy-SSA-Biologics Download A. Liu, B. Ueberroth, P. McGarrah, S. Buckner Petty, A. Kendi, J. Starr, T. Hobday, T. Halfdanarson, M. Sonbol ABSTRACT ID: 143 C11 - Comparative Analysis of Octreotide Long Acting Release (LAR) and Lanreotide in Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs): A Single Institution Experience Published in 2020 Listed under Clinical-Chemotherapy-SSA-Biologics Download S. Wu, P. Reta-Impey, N. Manivannan, S.H. Tirumani, P. Fu, S. Cao, S. Asa, A. Kardan, F. Liu, N. Avril, P. Wojtylak, R. Lee, D. Bajor, E. Selfridge, J. Saltzman, J. Hardacre, J. Ammori, J. Winter, A. Mohamed C12 - A Single-Centre Pilot Study for Radiosensitization of Everolimus with External Beam Radiotherapy for the Treatment of Metastatic Neuroendocrine Liver Metastasis Published in 2020 Listed under Clinical-Chemotherapy-SSA-Biologics Download S. Myrehaug, D. Chan, V. Rodriguez Freixinos, C. Law, J. Hallet, J. Hudson, S. Singh ABSTRACT ID: 152 C13 - Efficacy of FOLFOX With Or Without Bevacizumab in Patients With Aggressive Pancreatic NETs After Prior Capecitabine/Temozolomide Published in 2020 Listed under Clinical-Chemotherapy-SSA-Biologics Download T. Al-Toubah, B. Morse, E. Pelle, J. Strosberg ABSTRACT ID: 156 C14 - Efficacy and Toxicity Analysis of Capecitabine and Temozolomide in Neuroendocrine Neoplasms Published in 2020 Listed under Clinical-Chemotherapy-SSA-Biologics Download T. Al-Toubah, E. Pelle, T. Valone, M. Haider, J. Strosberg ABSTRACT ID: 157 C15 - Concurrent Everolimus with Hepatic Transarterial Bland Embolotherapy (Evero-Embo) in Patients with Metastatic Well Differentiated Neuroendocrine Tumor (NET) Published in 2020 Listed under Clinical-Chemotherapy-SSA-Biologics Download L. Anthony, G. Gabriel, A. Chauhan, R. El Khouli ABSTRACT ID: 159 C16 - Comparative Outcomes of Second Line Topoisomerase I Inhibitor- Containing Therapies on Extrapulmonary Neuroendocrine Carcinoma Published in 2020 Listed under Clinical-Chemotherapy-SSA-Biologics Download H.-M. Yeung, K. Sreekrishnanilayam, C. Meeker, M. Deng, S. Agrawal, H. Abdullah, E. Ross, N. Vijayvergia ABSTRACT ID: 162 C17 - The Clinical Impact of Serum Chromogranin-A in Patients with Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETS) Published in 2020 Listed under Clinical-Chemotherapy-SSA-Biologics Download S. Wu, P. Reta-Impey, N. Manivannan, P. Fu, S. Cao, S. Asa, S.H. Tirumani, J. Davidson, A. Kardan, N. Avril, P. Wojtylak, D. Bajor, R. Lee, E. Selfridge, J. Saltzman, J. Ammori, J. Hardacre, J. Winter, A. Mohamed ABSTRACT ID: 163 C18 - Avelumab in Unresectable/ Metastatic, Progressive, Grade 2-3 Neuroendocrine Neoplasms (NEN): Combined Results from NET-001 and NET-002 Trials Published in 2020 Listed under Clinical-Chemotherapy-SSA-Biologics Download D. Chan, V. Rodriguez Freixinos, M. Doherty, K. Wasson, N. Iscoe, W. Raskin, J. Hallet, S. Myrehaug, C. Law, A. Thawer, K. Nguyen, S. Singh ABSTRACT ID: 164 C19 - Urinary Neuroendocrine Neoplasms Treated in the “Modern Era”: A Multicenter Retrospective Review Published in 2020 Listed under Clinical-Chemotherapy-SSA-Biologics Download B. Le, P. McGarrah, J. Whitman, A. Paciorek, N. Raj, D. Reidy-Lagunes, H. Hauser, T. Le, J. Del Rivero, A. Apolo, E. Bergsland, T. Halfdanarson ABSTRACT ID: 185 C2 - Real-World Observational Study of Somatostatin Analogs and Rescue Medication Use for Neuroendocrine Tumors in Canada Published in 2020 Listed under Clinical-Chemotherapy-SSA-Biologics Download D. Rayson, V. Petrovic, C. Laforty, M. Badin, H. McKechnie ABSTRACT ID: 112 C20 - Efficacy of Somatostatin Analog (SSA) Monotherapy for Well-Differentiated Grade 3 (G3) Gastroenteropancreatic Neuroendocrine Tumors (NETs) Published in 2020 Listed under Clinical-Chemotherapy-SSA-Biologics Download P. McGarrah, A. Liu, T. Hobday, J. Starr, A. Kendi, R. Graham, T. Halfdanarson, M. Sonbol ABSTRACT ID: 200 C3 - Patient-Reported Activity Impairment, Work Productivity Loss, and Carcinoid Syndrome Outcomes: Interim Analyses of the XERMELO Patient Registry Published in 2020 Listed under Clinical-Chemotherapy-SSA-Biologics Download C. Darden, V. Joish, M. Price, D. Garbinsky, S. Schwartz, C. Warner, S. Wason, P. Lapuerta ABSTRACT ID: 113 C4 - Carcinoid Syndrome (CS) Improvements in Patients Receiving Telotristat Ethyl (TE): Findings from TELEPRO-II Published in 2020 Listed under Clinical-Chemotherapy-SSA-Biologics Download M. Kulke, V. Di Gialleonardo, V. Joish, K. Murali, H. Kennecke ABSTRACT ID: 115 C5 - Efficacy of Telotristat Ethyl (TE) in Patients with Progressive Neuroendocrine Tumor Disease: Real World Clinical Practice Experience Published in 2020 Listed under Clinical-Chemotherapy-SSA-Biologics Download E. Liu, D. Metz, V. Joish, V. Di Gialleonardo, K. Murali, M. Morse ABSTRACT ID: 117 C6 - Efficacy of Checkpoint Inhibitors in Neuroendocrine Neoplasms: The Mayo Clinic Experience Published in 2020 Listed under Clinical-Chemotherapy-SSA-Biologics Download J. Gile, A. Liu, P. McGarrah, R. Eiring, J. Starr, M. Sonbol, T. Hobday, T. Halfdanarson ABSTRACT ID: 125 C7 - Safety in Patients With Neuroendocrine Tumors Receiving Telotristat Ethyl (TE) With Peptide Receptor Radionuclide Therapy (PRRT) Published in 2020 Listed under Clinical-Chemotherapy-SSA-Biologics Download A. Chauhan, P. Binder, E. Tesfaye, K. Seth, P. Lapuerta ABSTRACT ID: 130 C8 - Lanreotide Autogel (LAN) 120 mg Every 14 Days in Progressive Pancreatic Neuroendocrine Tumors (panNETs): CLARINET FORTE Study Published in 2020 Listed under Clinical-Chemotherapy-SSA-Biologics Download M. Pavel, J. Ćwikła, C. Lombard-Bohas, I. Borbath, T. Shah, U.-F. Pape, X.-M. Truong Thanh, A. Houchard, P. Ruszniewski ABSTRACT ID: 135 C9 - Lanreotide Autogel (LAN) 120 mg Every 14 Days in Progressive Midgut Neuroendocrine Tumors (NETs): CLARINET FORTE Study Published in 2020 Listed under Clinical-Chemotherapy-SSA-Biologics Download M. Pavel, J. Ćwikła, C. Lombard-Bohas, I. Borbath, T. Shah, U.-F. Pape, X.-M. Truong Thanh, A. Houchard, P. Ruszniewski ABSTRACT ID: 136 Select the number of documents per page 5 10 15 20 25 30 50 100
